Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Worldwide Oral Mucositis Market Will Grow Steady at a Rate of 7% CAGR by 2023

Market Scenario

Oral Mucositis is a disorder in which an individual grows painful lesions of the mucus membranes of the mouth. It is a side effect of cancer treatment and typically increases in harshness as the dose of chemo or radiation therapy increases. Mucositis can have a devastating effect on a person’s nutritional status, because the oral pain related with the condition often prevents individuals from eating solid food, and sometimes even from swallowing. Most patients undergo chemotherapy on an outpatient basis and are admitted to the hospital if they develop fever and neutropenia, obvious infection, or some other complication. Yet, oral complications, when they arise in either the inpatient setting or the outpatient setting, are similar.

The market for Oral Mucositis will grow steady at a rate of 7% CAGR during the forecasted period 2017-2023. The increase in number of cancer patients and the use of chemotherapy are leading the growth of the market.

Key players of Global Oral Mucositis market:

Some of the players operating for the oral mucositis are

- Izun Pharmaceutical Ltd (US)
- Shoreline Pharmaceuticals Inc. (USA)
- Himalaya (India)
- AMAG Pharmaceuticals Inc. (USA)
- Kinnear Pharmaceuticals (US)
- Celleutix Corporation(USA)
- Soligenix Inc. (US)
- Oragenics (US)

https://www.medgadget.com/2017/09/worldwide-oral-mucositis-market-will-grow-steady-at-a-rate-of-7-cagr-by-2023.html